Optiver Holding B.V. Makes New $45.59 Million Investment in Haleon PLC Sponsored ADR $HLN

Optiver Holding B.V. acquired a new stake in Haleon PLC Sponsored ADR (NYSE:HLN) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 5,082,822 shares of the company’s stock, valued at approximately $45,593,000. Haleon makes up approximately 0.0% of Optiver Holding B.V.’s portfolio, making the stock its 19th biggest holding. Optiver Holding B.V. owned about 0.11% of Haleon as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the stock. Legacy Financial Advisors Inc. acquired a new stake in shares of Haleon in the third quarter valued at approximately $171,000. Citigroup Inc. lifted its holdings in Haleon by 7.0% during the 3rd quarter. Citigroup Inc. now owns 986,450 shares of the company’s stock worth $8,848,000 after buying an additional 64,298 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in shares of Haleon in the 3rd quarter valued at $103,000. King Luther Capital Management Corp increased its stake in shares of Haleon by 4.4% in the 3rd quarter. King Luther Capital Management Corp now owns 28,292 shares of the company’s stock valued at $254,000 after buying an additional 1,204 shares during the period. Finally, NewEdge Wealth LLC raised its position in shares of Haleon by 20.0% during the third quarter. NewEdge Wealth LLC now owns 77,238 shares of the company’s stock worth $719,000 after acquiring an additional 12,878 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Performance

Shares of HLN stock opened at $11.08 on Wednesday. Haleon PLC Sponsored ADR has a 12 month low of $8.71 and a 12 month high of $11.42. The company’s fifty day simple moving average is $10.40 and its 200-day simple moving average is $9.79. The firm has a market cap of $49.33 billion, a PE ratio of 28.41 and a beta of 0.19. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48.

Analysts Set New Price Targets

Several research analysts have recently issued reports on HLN shares. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. HSBC raised Haleon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft cut shares of Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Jefferies Financial Group reiterated a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.